22 COVID-19 vaccines enter clinical trials in China: health official
Xinhua |
Updated: 2021-07-08 19:36
Share
Share - WeChat
BEIJING - Twenty-two COVID-19 vaccines have been approved to enter clinical trials in China, a health official said Thursday.
To date, four COVID-19 vaccines have been granted conditional marketing approval and three have been authorized for emergency use within the country, said Yuan Lin, an official with the National Medical Products Administration (NMPA), at a press conference in Beijing.
By the end of June, the NMPA had granted emergency approval for clinical trials to 25 drugs intended for the treatment of COVID-19 and its indications, Yuan added.
- China has over 7.3m voluntary organ donors
- World's first hepatitis D monoclonal antibody drug administered in Beijing
- CPC Central Committee, Xi invite KMT chairperson to visit mainland
- Symposium on mainland's new five-year plan held in Taipei
- Macao intl parade highlights Maritime Silk Road as cultural bridge
- Chinese boy breaks history as world junior champion
